Diabetes Combos: Novo, Sanofi May Need New Treatment Paradigm To Match Products
Stepwise approach of endocrinologists may have to change to maximize uptake of insulin/GLP-1 combinations.
You may also be interested in...
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
US FDA’s PDUFA VIII Ideas Could Include Creating Regulatory Science Research Program
With regulatory science research already funded for generic drugs and biosimilars, CDER Director Patrizia Cavazzoni wants a program for prescription drugs considered for the next user fee renewal.